Menotropin HMG

Fertility Testosterone Support Spermatogenesis HPG Axis Post-Cycle Recovery Reproductive Health

75 - 150 IU, 2 - 3 x per week

SubQ

Starting from

R390

2 suppliers available - see pricing tab below

View Pricing & Buy

Dosage

75 - 150 IU, 2 - 3 x per week

Administration

SubQ

Category

Bioregulator

Overview

Menotropin, commonly known as Human Menopausal Gonadotropin (HMG), is a purified preparation containing both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) activity in roughly equal ratios. Originally derived from the urine of postmenopausal women and now also produced via recombinant methods, HMG is widely studied in fertility medicine and hormonal recovery research. It directly stimulates the gonads, making it valuable for protocols targeting both testosterone production and spermatogenesis or follicular development.

Mechanism of Action

HMG provides exogenous LH and FSH, bypassing the hypothalamus and pituitary to act directly on the gonads. In males, LH stimulates Leydig cells in the testes to produce testosterone, while FSH acts on Sertoli cells to support spermatogenesis. In females, FSH drives follicular development in the ovaries while LH supports ovulation and corpus luteum function. Unlike hCG (which mimics LH only) or Kisspeptin (which works upstream at the hypothalamus), HMG delivers the full LH/FSH signal directly to the gonadal tissue, making it particularly relevant for fertility-focused protocols where both hormones are needed.

Key Benefits

Provides both LH and FSH activity in a single compound
Directly stimulates testosterone production in males
Supports spermatogenesis and sperm quality
Promotes follicular development in female fertility research
Useful in post-cycle recovery protocols for restoring testicular function
Restores testicular volume after suppression
Complements other HPG axis recovery agents

Side Effects & Safety

Injection site redness, swelling, or irritation
Possible mild headache, fatigue, or mood changes
Risk of estrogen elevation due to increased testosterone aromatization
Potential for ovarian hyperstimulation in female research contexts
May cause gynecomastia if estrogen is not managed
Not approved for general human use; sold strictly for research purposes
Long-term safety profile outside of clinical fertility use is limited
Consult a qualified medical professional before any use

Research & Stacking Notes

Frequently paired with hCG in post-cycle recovery research for full LH/FSH coverage Often combined with SERMs (Clomid, Tamoxifen) in HPG axis restoration protocols Pairs with Kisspeptin-10 for upstream and downstream HPG axis support Commonly stacked with aromatase inhibitors to manage estrogen conversion Typical research dosing: 75-150 IU, 2-3 times per week Reconstitute with bacteriostatic water; refrigerate after mixing Use within 2-3 weeks of reconstitution for peptide stability Often used in cycles of 4-12 weeks depending on research protocol

Stacks Well With

Kisspeptin

Bioregulator

Select your preferred supplier and add to cart. Prices shown include VAT.

Supplier / Lab	Strength / Volume	Price	Availability
UP UPA Labs Australia	75iu 1 Vial	R390	In Stock
VM VMed South Africa	75iu 1 Vial	R820	In Stock

All peptides are for research purposes only. Not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before use.